INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, with a reported fiveyear survival rate of seven percent (1). Over 48,000 PDACs are estimated to be diagnosed in the United States in 2015. Of these, up to 10% occur in families with at least two affected firstdegree relatives, and these are designated familial pancreatic cancers (FPC) (2). Individuals with a family history of PDAC carry a 2.3 to 32-fold increased risk of developing the disease, depending upon number of affected family members (3) . In some FPC kindreds, the aggregation of pancreatic cancer may be due to environmental factors or stochastic events, but many are thought to be caused by inherited genetic susceptibility (4) .
Knowledge of the genes responsible for an inherited susceptibility to pancreatic cancer is important for a number of reasons. First, early detection can be targeted to mutation carriers, and pancreatic neoplasms detected at an earlier stage, when therapeutic interventions with curative potential are still available (5) . Second, as most previously reported FPC susceptibility genes also increase risk for malignancies other than pancreatic cancer, these extra-pancreatic neoplasms can be screened for as well (6) . Third, elucidation of the genetic basis of FPC susceptibility offers opportunities for personalized therapies, as demonstrated by patients whose pancreatic cancers harbor defects in homologous recombination arising from bi-allelic inactivation of BRCA1, BRCA2 or PALB2. In these patients, targeting DNA repair with poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors, platinum compounds, or mitomycin C can result in major therapeutic benefits (7) . Finally, identifying causal FPC genes will provide novel insights into PDAC tumorigenesis.
Page 6 of 34 identified as FPC susceptibility genes, together explaining 3 -5% of FPC cases (8, 9) . In a further 8 -15% of FPC patients, the increased risk of pancreatic cancer can be attributed to 10 other previously reported FPC susceptibility genes, including BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PMS2, PRSS1, STK11, and TP53 (10) (11) (12) (13) (14) (15) (16) . The genetic basis underlying disease susceptibility in the remaining 80 -90% of FPC patients is unknown.
To explore the genetic basis of FPC in detail and identify candidate susceptibility genes, we performed whole genome sequencing on the germline DNA of 638 FPC patients from 593
kindreds. This sequencing was supplemented with the whole exome sequencing of surgically resected PDACs from 39 FPC patients. The results identify of novel candidate FPC susceptibility genes and validate the importance of established FPC genes. In addition, our results suggest that somatic mutations in hematologic malignancy driver genes can confound the findings of germline genomic sequencing studies in older populations. Finally, we provide an unprecedentedly large resource of deep, whole genome sequence data that can be used for pancreatic cancer research.
Research. Local Ancestry in adMixed Populations (LAMP). FPC patients were predominantly of European ancestry (95.9%), but patients of African (2.8%), and Asian (1.3%) ancestry were also represented ( Table 1) . Identity-by-descent analysis confirmed expected familial relationships.
Analysis of premature truncating variants
Given that most high-penetrance disease associated variants so far identified are located in coding regions (18) , we focused our analyses on genetic variants located in these regions. The functional significance of missense variants is often unclear. We therefore began our analysis with premature truncating variants (PTVs), as these almost always affect protein function. As FPC is a rare disease and common PTVs are less likely confer a high risk of FPC susceptibility due to negative selective pressures, we concentrated our analyses on private heterozygous PTVs.
We arbitrarily selected one sequenced member from each of the 593 FPC kindreds and positively-filtered variants using the following criteria (Fig. 1A) : i) nonsense variants, splice site variants, and frameshift INDELs, ii) heterozygous in the germline, iii) less than 0.5% minor allele frequency in the 1000 Genomes Project or Exome Variant Server (EVS), iv) and present in only one FPC patient, i.e., "private" (19, 20) . Finally, we selected high quality rare heterozygous PTVs by filtering for variants with: i) a mappability score of at least 0.5, and ii) no more than one additional genomic locus as assessed by BLAT (21, 22) . Using these filters, we identified 6,114 private heterozygous PTVs, in 4,553 genes.
In order to identify novel FPC susceptibility genes, we then we ranked 20,049 coding genes by the number of private heterozygous PTVs that they harbored (Supplementary Table   S1 ). Several of the 12 previously reported FPC susceptibility genes were highly ranked, providing support for this general approach. For example, the highest ranked gene was ATM with 19 private heterozygous PTVs. Similarly, PALB2 (five heterozygous PTVs) and CDKN2A (four heterozygous PTVs) were also ranked highly. While most genes harbored only one private heterozygous PTV and presumably do not play a common role in FPC susceptibility, 1,077 genes contained 2 or more private heterozygous PTVs (Fig. 1B) We detected private heterozygous PTVs in TET2 (n=9), DNMT3A (n=7), and ASXL1(n=5) ( Table 2) . Recent evidence has indicated that somatic mutations in genes contributing to hematologic malignancies are detectable in the blood of older individuals, suggesting a potentially pre-leukemic clonal hematopoiesis (25) (26) (27) (28) . As DNA used for whole genome sequencing was primarily derived from peripheral white blood cells (Table 1) , when possible, we sequenced these mutations in DNA from a second non-blood source (two patients, FPC0072 and FPC0083 in Supplementary Table S2 ). In both cases, the mutation was not found or was found at much lower levels than observed in DNA from blood. Suggesting these mutations may be somatic in nature.
It is possible that rare heterozygous PTVs in our FPC cohort contribute to susceptibility, as would be the case for founder mutations. Allowing the same heterozygous PTV to occur in as many as 10 FPC patients (rather than in only one FPC patient) did not significantly change the outcome our analysis. Specifically, using the same FPC patients, 9,689 heterozygous PTVs across 5,116 genes were observed, and 80% of these were also identified when filtering for only private mutations.
In-depth analysis of selected genes
We conducted an in-depth analysis of 87 genes that included: i) previously reported FPC susceptibility genes, ii) genes associated with hereditary cancers and, iii) genes mutated in hereditary pancreatitis (Supplementary Table S3 ). As these genes had already been associated with disease, we were able expand our filter beyond just PTV's to evaluate all variants based on their functional consequences, minor allele frequencies in the 1000 Genomes Project and EVS, and ClinVar classification (19, 20, 29) .
Research. We identified SNVs, insertions and deletions (INDELs) less than 300 bp in length, and structural variant deletions (SVDs) greater than 300 bp in length that affected the coding regions of these 87 genes. Variants were classified as either benign, of unknown significance (VUS), or deleterious according to the criteria detailed in Table 3 . Among all 638 FPC patients sequenced, 92,933 sequence variants were identified in these 87 genes (Supplementary Table S4 ). Among the 593 unrelated FPC patients, 86,486 sequence variants were identified, 194 of which were defined as deleterious. In the 12 reported FPC susceptibility genes, there were 62 deleterious variants in 58 FPC kindreds (9.8% of FPC kindreds; 95% confidence interval: 7.6 -12.4%). In 32 FPC patients, deleterious variants in two or more of the 87 genes analyzed in depth were observed (Supplementary Table S5 ). Of these patients, four had deleterious variants in two FPC susceptibility genes: one patient had an ATM and a PALB2 deleterious variant, one patient had two deleterious TP53 variants, and two patients had deleterious variants in both BRCA1 and BRCA2. A further, 17 patients had a deleterious variant in an FPC susceptibility gene in addition to a deleterious variant in a hereditary cancer or hereditary pancreatitis gene.
It should be noted that FPC patients known to have a deleterious variant in reported FPC susceptibly genes prior to the start of this study were not selected for sequencing. Therefore, our analysis underestimates the true prevalence of previously reported FPC susceptibility genes for which clinical testing is not uncommon, such as BRCA1, BRCA2, CDKN2A, and PALB2. At the time of patient selection, ATM was not commonly tested, and we identified 21 patients from 20 kindreds with deleterious variants in this gene (3.4% of FPC kindreds; 95% confidence interval: 2.2 -5.2%).
In addition to publicly available data from the 1000 Genomes Project and EVS, we compared our findings in the 87 selected genes to whole exome sequencing data from 967
Research. Table S4 and Supplementary Table S6 Table S8 ). These associations remained significant when the analysis was restricted to individuals with greater than 80% European genetic ancestry.
(Supplementary Table S8 ).
Analysis of variant segregation in affected members of a kindred
We hypothesized that a deleterious variant shared among family members with pancreatic cancer was more likely to be associated with pancreatic cancer susceptibility.
Therefore, we assessed segregation of: i) private heterozygous PTVs across the exome, and ii) Seventeen deleterious variants in one of the 87 genes analyzed in-depth occurred in an FPC patient from a family in which another affected family member had been sequenced.
Deleterious variants included six frameshift deletions, two nonsense SNVs, two splice-site SNVs, and nine nonsynonymous SNVs (Supplementary Table S10 ). In 13 of the 17 cases, the deleterious variant did not perfectly segregate among affected family members. For example, we observed non-segregation of deleterious variants in ATM (one kindred with 1 of 2 affected members carrying a variant), CDKN2A (two kindreds each with 2 of 3 affected members carrying a variant), BRCA1 (one kindred with 1 of 2 members carrying a variant), and PALB2 (one kindred with 1 of 2 members carrying a variant).
Somatic alterations in familial pancreatic cancers
Hereditary cancer susceptibility genes are often tumor suppressors in which a deleterious variant in the germline of an individual is accompanied by a second somatic event resulting in biallelic loss of the gene in the tumor (18, 31) . To help identify candidate susceptibility genes through the identification of such second somatic "hits", we sequenced the exomes of 39 pancreatic cancers resected from FPC patients. Whole exome sequencing rather than whole genome sequencing was conducted because PDACs often contain a significant proportion of non-neoplastic cells (even after careful microdissection). Therefore, we could increase coverage to 100X, enhancing sensitivity of somatic mutation detection. Because of the low neoplastic content of these lesions, we did not identify losses of heterozygosity or changes in copy number, and examined only somatic mutations. Exome sequencing revealed 1,409 somatic mutations, with an average of 36 mutations per tumor (Supplementary Table S11 ). As expected, somatic mutations in KRAS and TP53 were the most common, occurring in 84.6% and 71.8%, respectively (Supplementary Table S12) (32) . Other genes somatically mutated in the cancers included SMAD4 (33.3%) and CDKN2A (12.8%). The prevalence of KRAS, TP53, SMAD4, and CDKN2A mutations is similar to previous reports of both sporadic and familial pancreatic cancer Table S12 ). FPC patients with a somatic mutation in one of these genes did not have a deleterious germline variant in the same gene. Furthermore, one patient had a deleterious germline variant in a previously reported FPC susceptibility gene (FPC0347; PALB2) but did not have a second somatic mutation in the tumor. Although, loss-ofheterozygosity at this locus could not be ruled out.
Of the 4553 genes that harbored at least one private heterozygous PTV in our genomewide analysis, 366 (8.0%) also were found to have a somatic mutation in at least one sequenced pancreatic tumor (Supplementary 
DISCUSSION
The genetic basis of familial pancreatic cancer is poorly defined. We conducted germline whole genome sequencing of 638 familial pancreatic cancer patients and demonstrate that inherited pancreatic cancer is highly heterogeneous. This heterogeneity has significant implications for the management of patients with a family history of this disease.
Our results provide strong evidence in support of previously reported FPC susceptibility genes, such as ATM, BRCA2, CDKN2A, and PALB2 elevating risk of pancreatic cancer. As well, our study suggests that deleterious variants in the candidate genes BUB1B, CPA1, FANCC, and FANCG, are more frequent in patients with familial pancreatic cancer. (Table 2 and   Supplementary Table S8 ). Interestingly, many of these candidate genes are involved in processes regulating DNA repair or chromosomal stability, just as are the previously identified ATM, BRCA2, and PALB2 genes.
BUB1B encodes a protein involved in spindle-assembly checkpoint and germline mutations in BUB1B are known to predispose to premature chromatid separation syndrome and other cancer types (4, 35) . Heterozygous, inactivating mutations in BUB1B were present in three FPC patients. In one FPC patient, a second affected relative was available and in this case, the BUB1B variant was not present (Supplementary Table 10 Our results also suggest deleterious germline variants in CPA1 may be more frequent in FPC patients. Four heterozygous nonsense variants in CPA1 were found in FPC patients (three chr7:130020952_C>T; p.R27X variants and one chr7:130021680_C>A; p.Y119X variant). This finding is intriguing given that deleterious variants in this gene have recently been shown to predispose to chronic pancreatitis and that chronic pancreatitis is strongly associated with an increased risk of pancreatic cancer (16, 36) . Two of the FPC patients with a deleterious CPA1 variant reported a history of pancreatitis approximately 1 year before diagnosis. Intriguingly, 3.1% of recently diagnosed pancreatic cancer patients report a history of pancreatitis within a year of diagnosis (37) . As the p.R27X variant identified in FPC patients has previously been shown to be functionally defective, a history of subclinical chronic pancreatitis cannot be ruled out (36) .
Ten patients harbored the same deleterious variant in APC (chr5:112175211_T>A; p.I1307K). As this APC variant is prevalent in Jewish populations and the proportions of FPC patients and BCCS samples of Jewish ancestry are unknown, further studies to validate this association are warranted, especially considering the equivocal role that the APC gene broadly plays in FPC susceptibility (38) (39) (40) .
There are at least three observations from our study that are likely to have an impact on research involving other hereditary cancers. The first is that FPC appears to be heterogeneous with respect to its genetic underpinnings. Though this statement is not surprising given prior research on FPC, it was possible that a previously undiscovered gene was responsible for the Second, and more subtly, we observed that variants in well-recognized FPC susceptibility genes were often not present in other affected individuals from the same family (Supplementary Table S10 ). Segregation of variants among affected members is the hallmark of susceptibility to any disease, and provides the conceptual foundation for linkage analysis. The extent of phenocopies in our study, though surprising in some respects, is not without precedent. In one of the first reports of a gene conferring susceptibility to cancer, it was noted that a particular TP53 gene mutation was not present in a young patient with breast cancer from a Li-Fraumeni family (41) . This patient, in retrospect, was obviously a phenocopy. In our cases, the lack of coinheritance could either be explained by phenocopies, the possibility that multiple deleterious variants are responsible for the phenotype within that family, or that the variant we classified as deleterious was not responsible for the phenotype. It is of interest to note, that many of the previously reported pancreatic cancer susceptibility genes, such as BRCA1, PALB2, CDKN2A, and ATM, as well as our candidate genes, would be eliminated as susceptibility genes if phenocopies were not considered (Supplementary Table S10) .
A third point raised by our results pertains to the nature of the peripheral white blood cell DNA that is used for virtually all large-scale genomic studies. We observed multiple private heterozygous PTVs in ASXL1, DNMT3A, and TET2 in FPC patients, which would suggest they are FPC susceptibility genes. Given these genes have been shown to be somatically mutated in the blood of phenotypically normal individuals (25) (26) (27) (28) , we attempted to confirm the germline origin of these variants in two FPC patients by sequencing DNA from a second tissue. In both cases, our results indicated that these variants were somatic in nature. These unexpected observations emphasize that DNA derived from peripheral white blood cells cannot always be equated with germline DNA, especially in older individuals. This is of particular importance given that many sequencing studies, including ours use publically available control data where age data are not available and the age distribution of the controls may be different from that of the study population. Thus, somatic mutations in peripheral white blood cells could lead to false positive associations, particularly for diseases strongly related to aging.
Finally, we focused on rare PTVs because these variants alter their encoded proteins in an extreme fashion and are predicted to inactivate them. There are, however, other types of variants that may contribute to FPC susceptibility. Further studies will be necessary to delineate the role of missense and non-coding variants in FPC as current algorithms to discriminate deleterious from benign variants are not accurate. In addition, large INDELs may be poorly detected our sequencing method. As such, alternative approaches may be necessary to determine the contribution of large INDELs to FPC susceptibility. Recognizing the need for long-term research, we chose to employ whole genome rather than exome sequencing. Whole genome analyses provide a more complete resource to the pancreatic cancer research community. As more information about gene regulatory regions become available through projects such as ENCODE, and as more control individuals' whole genome sequences becomes publicly available, the utility of the resource provided herein will correspondingly increase. 
METHODS

Institutional approval and informed consent
This study followed the recommendations of the Declaration of Helsinki. Each study site obtained Institutional Review Board approval for their study protocols. Informed consent was obtained from all study participants at their respective institution. 
Familial pancreatic cancer (FPC) patient samples
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 9, 2015; DOI: 10.1158/2159-8290.CD-15-
Identify by descent (IBD) and Local Ancestry in adMixed Populations (LAMP) analysis of FPC patients
IBD sharing analysis was performed on FPC patients using 22,458 independent single nucleotide polymorphisms (SNPs) with an R2 cutoff of 0.0001 and outside regions of high linkage disequilibrium (LD). Reported familial relationships were confirmed.
LAMP analysis was performed using hg19 genomic coordinates and strand alignment was completed with ShapeIT v2 (44, 45) . Only SNPs common to both the 1000 Genomes Project reference panel and the FPC patient cohort were analyzed (669,977 SNPs) (19). Ancestral allele frequencies were defined using 1000 Genomes project EUR, AFR, and ASN population groups. Variants were annotated as described for whole genome sequencing of FPC patients.
Confirmation of TET2 and ASXL1 variants
Confirmation of variants was performed on DNA from blood and formalin-fixed paraffin embedded tissues using the Safe-Sequencing System (Safe-SeqS) as previously described (49) .
Primer sequences used to detect the TET2 (g.chr4:106196537_C>T;p.Q1624X) variant were: cacacaggaaacagctatgaccatgGGGGAGAATAGGAACCCAGA and cgacgtaaaacgacggccagtNNNNNNNNNNNNNNAATCCCATGAACCCTTACCC. Primer sequences used to detect the ASXL1 variant (g.chr20:31022414_T>TA; p.fs) were: cacacaggaaacagctatgaccatgCTCTGCCACCTCCCTCATC and cgacgtaaaacgacggccagtNNNNNNNNNNNNNNGGACCCTCGCAGACATTAAA. Where N's denote degenerate bases, with an equal representation of A, C, T, and G.
Statistical analyses
Two sided p-values were calculated using a Fisher's Exact Test. False discovery rate was calculated using Benjamini-Hochberg procedure. A p-value of less than 0.05 was considered significant.
Data availability
Whole genome and exome sequencing data are available (50) . Users must obtain Institutional Review Board approval from their institutions and agree to policies that maintain patient privacy prior to use.
Author contributions
Study design: N.J.R., A.N., G.M.P., M.G., N.P., J.R.E., K.W.K., B.V., R.H.H., A.P.K.
Research. Tables   Table 1. Characteristics of the whole genome sequenced FPC patients Table 2 . Genes with three or more private heterozygous PTVs in unrelated FPC patients Table 3 
LEGENES FOR TABLES AND FIGURES
